KOREA ARLICO PHARM CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4,800 KRW | -0.10% |
|
-1.84% | -15.79% |
| 2023 | Korea Arlico Pharm Co.,Ltd. announced that it has received KRW 10 billion in funding | CI |
| 2023 | Korea Arlico Pharm Co.,Ltd. announced that it expects to receive KRW 10 billion in funding | CI |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 118,505 | 137,624 | 142,830 | 117,712 | 100,392 | 87,364 |
| Enterprise Value (EV) 1 | 115,561 | 125,219 | 133,016 | 101,565 | 99,285 | 102,864 |
| P/E ratio | 59.3 x | 8.48 x | 11.1 x | 23.5 x | 12.3 x | 54.8 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 1.24 x | 1.19 x | 1.14 x | 0.84 x | 0.6 x | 0.47 x |
| EV / Revenue | 1.21 x | 1.08 x | 1.07 x | 0.72 x | 0.59 x | 0.55 x |
| EV / EBITDA | 13.4 x | 8.79 x | 10.5 x | 13.7 x | 7.65 x | 13.1 x |
| EV / FCF | -5.35 x | 18.3 x | -17.4 x | 38.4 x | -5.93 x | -5.18 x |
| FCF Yield | -18.7% | 5.47% | -5.74% | 2.61% | -16.9% | -19.3% |
| Price to Book | 1.91 x | 1.9 x | 1.71 x | 1.42 x | 1.11 x | 0.96 x |
| Nbr of stocks (in thousands) | 15,113 | 15,373 | 15,469 | 15,327 | 15,327 | 15,327 |
| Reference price 2 | 7,841 | 8,952 | 9,233 | 7,680 | 6,550 | 5,700 |
| Announcement Date | 19-03-01 | 20-02-29 | 21-03-01 | 22-03-01 | 23-03-01 | 24-02-29 |
1KRW in Million2KRW
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 95,338 | 115,793 | 124,809 | 140,157 | 167,737 | 187,155 |
| EBITDA 1 | 8,595 | 14,251 | 12,629 | 7,400 | 12,977 | 7,844 |
| EBIT 1 | 7,367 | 12,538 | 10,599 | 4,794 | 9,864 | 3,073 |
| Operating Margin | 7.73% | 10.83% | 8.49% | 3.42% | 5.88% | 1.64% |
| Earnings before Tax (EBT) 1 | 2,078 | 12,151 | 9,728 | 5,605 | 8,391 | 3,476 |
| Net income 1 | 1,218 | 10,031 | 8,372 | 4,930 | 8,034 | 3,061 |
| Net margin | 1.28% | 8.66% | 6.71% | 3.52% | 4.79% | 1.64% |
| EPS 2 | 132.2 | 1,055 | 831.0 | 326.9 | 532.0 | 104.0 |
| Free Cash Flow 1 | -21,618 | 6,847 | -7,641 | 2,647 | -16,738 | -19,870 |
| FCF margin | -22.68% | 5.91% | -6.12% | 1.89% | -9.98% | -10.62% |
| FCF Conversion (EBITDA) | - | 48.05% | - | 35.76% | - | - |
| FCF Conversion (Net income) | - | 68.26% | - | 53.69% | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 19-03-01 | 20-02-29 | 21-03-01 | 22-03-01 | 23-03-01 | 24-02-29 |
1KRW in Million2KRW
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | 15,499 |
| Net Cash position 1 | 2,944 | 12,405 | 9,814 | 16,146 | 1,107 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | 1.976 x |
| Free Cash Flow 1 | -21,618 | 6,847 | -7,641 | 2,647 | -16,738 | -19,870 |
| ROE (net income / shareholders' equity) | 2.99% | 15.1% | 11.2% | 6.21% | 9.47% | 3.45% |
| ROA (Net income/ Total Assets) | 5.47% | 6.83% | 5.78% | 2.59% | 4.49% | 1.17% |
| Assets 1 | 22,258 | 146,776 | 144,730 | 190,320 | 178,933 | 260,637 |
| Book Value Per Share 2 | 4,106 | 4,723 | 5,400 | 5,404 | 5,898 | 5,933 |
| Cash Flow per Share 2 | 155.0 | 798.0 | 383.0 | 634.0 | 1,558 | 1,270 |
| Capex 1 | 17,454 | 2,646 | 9,389 | 5,268 | 18,974 | 23,385 |
| Capex / Sales | 18.31% | 2.28% | 7.52% | 3.76% | 11.31% | 12.49% |
| Announcement Date | 19-03-01 | 20-02-29 | 21-03-01 | 22-03-01 | 23-03-01 | 24-02-29 |
1KRW in Million2KRW
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -15.79% | 53.12M | |
| +20.76% | 43.59B | |
| +28.00% | 22.54B | |
| +20.25% | 15.73B | |
| +18.82% | 14.33B | |
| +55.83% | 12.75B | |
| -0.05% | 6.79B | |
| -12.70% | 6.48B | |
| -8.87% | 5.73B | |
| +14.65% | 5.67B |
- Stock Market
- Equities
- A260660 Stock
- Financials Korea Arlico Pharm Co.,Ltd.
